Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 30, 2015 12:20 AM ET

Personal Products

Company Overview of Famy Care Ltd.

Company Overview

Famy Care Ltd. manufactures and supplies female contraceptive pills, injectables, and devices. It offers oral and emergency contraceptives, intra uterine devices, tubal ligation rings, progestagen only pills, hormonal tablets, and cancer detection kits. Famy Care Ltd. was founded in 1987 and is based in Mumbai, India.

Brady House

3rd Floor

12/14, Veer Nariman Road


Mumbai,  400001


Founded in 1987


91 22 3028 9655


91 22 3021 5553

Key Executives for Famy Care Ltd.

Famy Care Ltd. does not have any Key Executives recorded.

Famy Care Ltd. Key Developments

TA Associates Reportedly In Talks To Acquire Famy Care's Stake

TA Associates Management, L.P. is in advanced talks to acquire a 35% stake in Famy Care Ltd. from AIF Capital Limited and Famy Care Ltd.'s promoters for $200 million, The Economic Times reported citing three people involved in the deal. The deal is expected to be signed post Diwali. Credit Suisse AG has been tapped by TA Associates Management, L.P. Naveen Wadhera, Asia Co-Head of TA Associates Management, L.P. did not respond to emailed queries.

Actavis Announces Agreement Related to Generess FE Patent Challenge Litigation

Actavis plc announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess(R) FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets). Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess(R) FE under its pending Abbreviated New Drug Application (ANDA) beginning on April 1, 2015. Alternatively, Mylan will be permitted to launch an authorized generic version of Actavis' product beginning on October 1, 2015. Other terms of the settlement were not disclosed. Actavis remains in litigation with Lupin Ltd. in connection with Lupin's pending ANDA for a generic version of Generess(R).

Recent Private Companies Transactions

February 2, 2015
Famy Care Ltd., Certain Female Health Care Businesses

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Famy Care Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at